Core Viewpoint - SOPHiA GENETICS reported strong preliminary financial results for Q4 and full year 2025, with expectations of 20-22% revenue growth in 2026 and announced an executive transition plan promoting Ross Muken to CEO effective July 1, 2026 [1][2][3] Financial Performance - Q4 2025 revenue is projected to be at least $21 million, reflecting a year-over-year increase of approximately 20% [6] - The company performed over 105,000 analyses on SOPHiA DDM™ in Q4 2025, marking a 16% year-over-year growth [6] - Full year 2025 revenue is approximately $77 million, representing an 18% year-over-year increase [6] - The total revenue for 2026 is guided to be between $92 million and $94 million, indicating a year-over-year growth of approximately 20% to 22% [7] Executive Transition - Ross Muken, currently President and a key executive for five years, will succeed Jurgi Camblong as CEO [3][5] - Jurgi Camblong will transition to Executive Chairman, focusing on strategic initiatives and technology innovation [4][5] - Kevin Puylaert has been appointed Chief Sales Officer effective January 2026, bringing over 10 years of experience with the company [10] Growth Catalysts - The company anticipates growth drivers in 2026, including advancements in its Liquid Biopsy application MSK-ACCESS powered by SOPHiA DDM™, opportunities in the U.S. market, and a revitalized BioPharma business [2]

Core Viewpoint - Whitehawk Therapeutics Inc. announced a multi-year collaboration with Tempus AI aimed at advancing biomarker-driven research, which has influenced its stock performance despite a recent drop in after-hours trading [2]. Group 1: Collaboration Details - The partnership with Tempus AI will utilize its proprietary real-world dataset to support the development of Whitehawk's oncology pipeline [2]. - The collaboration announcement gained traction on social media, indicating potential investor interest and market engagement [2]. Group 2: Recent Earnings Performance - Whitehawk reported a loss of $0.76 per share for the second quarter, missing expectations of a $0.09 gain, and reported no revenue for the quarter, falling short of the $60 million estimate [3]. - The next earnings report is scheduled for November 15 [3]. Group 3: Stock Performance - Whitehawk's shares have gained 21.96% over the past year and risen 33.85% in the past month, although the stock is down 17.41% year-to-date in 2025 [4]. - The market capitalization of Whitehawk is $122.42 million, with shares trading between $1.39 and $3.81 over the past year and an average daily trading volume of about 118,820 shares [4]. Group 4: Stock Trend Analysis - Benzinga Edge Stock Rankings indicate that WHWK has a positive price trend across all time frames, suggesting favorable market sentiment [5].